September 15, 2015

Press Release

Mitsubishi Tanabe Pharma Corporation

MT-4666 in Alzheimer’s Disease
Discontinuation of Global Phase 3 Clinical Trial Program in Japan

Osaka, Japan, September 15, 2015—Mitsubishi Tanabe Pharma Corporation (head office: Osaka; President & CEO: Masayuki Mitsuka) announced today that the Company discontinued a global phase 3 clinical trial program of MT-4666 (EVP-6124/encenicline) in patients with Alzheimer’s disease in Japan, which had been jointly-conducted with FORUM Pharmaceuticals Inc. (Massachusetts, U.S., formerly EnVivo Pharmaceuticals, Inc.).

MT-4666 is a novel alpha-7 (α7) potentiator. In March 2009, Mitsubishi Tanabe Pharma acquired from FORUM exclusive R&D, sales, and manufacturing rights for MT-4666 in Japan and other Asian countries. In summer 2014, Mitsubishi Tanabe Pharma participated in FORUM’s global phase 3 clinical trial program in Japan. FORUM was advised that the trials have been placed on clinical hold by the U.S. Food and Drug Administration (FDA). A small number of serious gastrointestinal (GI) safety events reported in the Alzheimer’s disease studies prompted the clinical hold. Mitsubishi Tanabe Pharma also announced that the Company discontinued the global phase 3 clinical trial program in Japan as well as a long-term trial in Japan evaluating the benefit-risk balance of MT-4666, which was conducted by the Company. Regarding a phase 2 trial in Japan which is conducted by Mitsubishi Tanabe Pharma, administration of study medication has been completed in all patients.

Mitsubishi Tanabe Pharma contributes to the healthier lives of people around the world through the creation of pharmaceuticals.

<Contact for Inquiries>
Corporate Communications Department
Phone: +81 6-6205-5211